Literature DB >> 20435196

Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.

Marcello Disertori1, Federico Lombardi, Simona Barlera, Roberto Latini, Aldo P Maggioni, Prisca Zeni, Giuseppe Di Pasquale, Franco Cosmi, Maria Grazia Franzosi.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is a common arrhythmia that frequently recurs after restoration of sinus rhythm (SR). Identifying risk factors for recurrence may help define the best strategy for secondary prevention.
METHODS: The GISSI-AF trial enrolled 1,442 patients in SR with at least 2 documented AF episodes in the previous 6 months or after cardioversion in the last 2 weeks. Patients were randomized to valsartan or placebo; all other treatments for AF or underlying heart diseases were allowed. Primary end points were time to first recurrence of AF and proportion of patients with >1 AF episode during 1-year follow-up. We evaluated clinical and electrocardiographic baseline characteristics of all patients to identify independent predictors for AF recurrence using a Cox multivariable model.
RESULTS: Risk factors for AF recurrence were a history of 2 or more AF episodes in the previous 6 months, independent of the modality of SR restoration, spontaneous (HR 1.42, 95% CI 1.14-1.77, P = .002), or by cardioversion (HR 1.19, 95% CI 1.01-1.40, P = .038), and a lower heart rate during SR (HR 0.99, 95% CI 0.99-1.00, P = .052). The risk factors were the same for >1 AF recurrence. Patients treated with amiodarone had a lower risk for both end points (P < .0001 and P = .017), whereas those on diuretics had a greater risk (P = .009 and P = .003).
CONCLUSIONS: In the GISSI-AF study population, AF history had significant prognostic value independent of the modality of SR restoration. Amiodarone and diuretic treatment affected the rate of AF recurrence. 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20435196     DOI: 10.1016/j.ahj.2010.02.016

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

Review 1.  Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation.

Authors:  Rachel R Huxley; Kristian B Filion; Suma Konety; Alvaro Alonso
Journal:  Am J Cardiol       Date:  2011-04-27       Impact factor: 2.778

2.  Atrial fibrillation: Blockade of the renin-angiotensin system in atrial fibrillation.

Authors:  Nadzeya Kuzniatsova; Eduard Shantsila; Gregory Y H Lip
Journal:  Nat Rev Cardiol       Date:  2010-08       Impact factor: 32.419

3.  Prediction of ineffective elective cardioversion of atrial fibrillation: a retrospective multi-center patient cohort study.

Authors:  Tapio Hellman; Tuomas Kiviniemi; Tuija Vasankari; Ilpo Nuotio; Fausto Biancari; Aissa Bah; Juha Hartikainen; Marianne Mäkäräinen; K E Juhani Airaksinen
Journal:  BMC Cardiovasc Disord       Date:  2017-01-18       Impact factor: 2.298

4.  Family history as a risk factor for recurrent hospitalization for lone atrial fibrillation: a nationwide family study in Sweden.

Authors:  Bengt Zöller; Henrik Ohlsson; Jan Sundquist; Kristina Sundquist
Journal:  BMC Cardiovasc Disord       Date:  2012-12-10       Impact factor: 2.298

5.  Effects of Mineralocorticoid Receptor Antagonists on Atrial Fibrillation Occurrence: A Systematic Review, Meta-Analysis, and Meta-Regression to Identify Modifying Factors.

Authors:  Joachim Alexandre; Charles Dolladille; Laurent Douesnel; Jonaz Font; Rafal Dabrowski; Linda Shavit; Damien Legallois; Christian Funck-Brentano; Laure Champ-Rigot; Pierre Ollitrault; Farzin Beygui; Theodora Bejan-Angoulvant; Jean-Jacques Parienti; Paul Milliez
Journal:  J Am Heart Assoc       Date:  2019-11-12       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.